{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:42:15Z","timestamp":1776440535368,"version":"3.51.2"},"reference-count":83,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Obesity, a heterogeneous metabolic disease, is linked with severe comorbidities, prominently increasing morbidity and mortality. A weight loss between 5% and 10% is already sufficient to induce clinically relevant improvements in human health. Activation of energy expenditure through an impact on the brown and beige adipose tissues has recently become an interesting new target in obesity treatment. Obeticholic acid (OCA) is a semisynthetic derivative of the primary human bile acid, chenodeoxycholic acid. The compound is an agonist of farnesoid X receptor (FXR) and Takeda G protein-coupled receptor (TGR5), activating the cellular pathways such as fibroblast growth factor-19, tissue-specific uncoupling protein 1, or type 2 iodothyronine deiodinase associated with energy expenditure and brown adipose tissue activity. So far, OCA has been approved to treat primary biliary cholangitis. Interestingly, the drug demonstrated therapeutic effects in animal models of obesity. Preliminary results from the human studies show that OCA administration holds potential as a treatment option in obesity, although some adverse effects may occur. Long-term administration of OCA might constitute an attractive therapeutic add-on approach, complementary to the currently approved treatments. The design of OCA derivatives targeting similar mechanisms, yet with a better pharmacological profile, seems to be an exciting pathway in the search of novel anti-obesity drugs. Further clinical trials involving larger cohorts of patients, with and without comorbidities, are warranted to confirm the benefits and safety of OCA administration.<\/jats:p>","DOI":"10.3390\/jcm15083081","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:24:51Z","timestamp":1776435891000},"page":"3081","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Activation of Brown Adipocytes by Farnesoid X Receptor Agonist, Obeticholic Acid\u2014A Potential Novel Therapeutic Avenue in the Management of Obesity"],"prefix":"10.3390","volume":"15","author":[{"given":"Anna Maria","family":"D\u0105browska","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, Medical University of Lublin, Jaczewskiego Street 8b, 20-090 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miros\u0142awa","family":"Chwil","sequence":"additional","affiliation":[{"name":"Department of Botany and Plant Physiology, University of Life Sciences in Lublin, Akademicka 15, 20-950 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2704-528X","authenticated-orcid":false,"given":"Ewa M.","family":"Urba\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, Medical University of Lublin, Jaczewskiego Street 8b, 20-090 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1038\/s41467-026-69738-w","article-title":"Preclinical and clinical obesity: Prevalence, associations to cardiometabolic risk and response to lifestyle intervention in NHANES and the EPIC-Potsdam and TULIP studies","volume":"17","author":"Schiborn","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/dom.70271","article-title":"Newly defined clinical obesity versus body mass index-defined obesity: Differential risks of overall death and adverse events in a population-based cohort","volume":"28","author":"Lian","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Dabrowska, A.M., and Dudka, J. (2023). Mirabegron, a Selective beta3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug. J. Clin. Med., 12.","DOI":"10.3390\/jcm12216897"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Alberts, C., Owe-Larsson, M., and Urbanska, E.M. (2023). New Perspective on Anorexia Nervosa: Tryptophan-Kynurenine Pathway Hypothesis. Nutrients, 15.","DOI":"10.3390\/nu15041030"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"eabl7398","DOI":"10.1126\/science.abl7398","article-title":"Integrative neurocircuits that control metabolism and food intake","volume":"381","author":"Bruning","year":"2023","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100002","DOI":"10.1124\/pharmrev.123.001045","article-title":"Emerging pharmacotherapies for obesity: A systematic review","volume":"77","author":"Kokkorakis","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1080\/14656566.2016.1233177","article-title":"Beta3-adrenoreceptor agonist mirabegron\u2014A potential antiobesity drug?","volume":"17","author":"Hainer","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13679-026-00701-y","article-title":"Decoding Adipose Tissue Phenotypic Switching: From Mechanisms to Computational Drug Discovery","volume":"15","author":"Ye","year":"2026","journal-title":"Curr. Obes. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bae, Y.A., and Cheon, H.G. (2026). Adipocyte Browning: A Promising Avenue in Anti-Obesity Therapy. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27031321"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1126\/science.1079857","article-title":"Obesity and the environment: Where do we go from here?","volume":"299","author":"Hill","year":"2003","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.cmet.2015.07.002","article-title":"The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity","volume":"22","author":"Broeders","year":"2015","journal-title":"Cell Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3892\/etm.2021.10423","article-title":"Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat","volume":"22","author":"Zhang","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-016-0616-x","article-title":"Obeticholic Acid: First Global Approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1210\/endrev\/bnac015","article-title":"Brown Adipose Tissue-A Translational Perspective","volume":"44","author":"Carpentier","year":"2023","journal-title":"Endocr. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.biochi.2016.09.007","article-title":"Origins and early development of the concept that brown adipose tissue thermogenesis is linked to energy balance and obesity","volume":"134","author":"Trayhurn","year":"2017","journal-title":"Biochimie"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e3594","DOI":"10.1002\/dmrr.3594","article-title":"Brown adipose tissue and regulation of human body weight","volume":"39","author":"Harb","year":"2023","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e139160","DOI":"10.1172\/jci.insight.139160","article-title":"beta3-Adrenergic receptors regulate human brown\/beige adipocyte lipolysis and thermogenesis","volume":"6","author":"Cero","year":"2021","journal-title":"JCI Insight"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1172\/JCI134892","article-title":"The beta3-adrenergic receptor agonist mirabegron improves glucose homeostasis in obese humans","volume":"130","author":"Finlin","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1172\/JCI136476","article-title":"Might beta3-adrenergic receptor agonists be useful in disorders of glucose homeostasis?","volume":"130","author":"Flier","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/1440-1681.13566","article-title":"The effects of mirabegron on obesity-induced inflammation and insulin resistance are associated with brown adipose tissue activation but not beiging in the subcutaneous white adipose tissue","volume":"48","author":"Calmasini","year":"2021","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_21","first-page":"5305","article-title":"Chenodeoxycholic acid attenuates high-fat diet-induced obesity and hyperglycemia via the G protein-coupled bile acid receptor 1 and proliferator-activated receptor gamma pathway","volume":"14","author":"Chen","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Floreani, A., Gabbia, D., and De Martin, S. (2022). Obeticholic Acid for Primary Biliary Cholangitis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102464"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Li, C., Yang, J., Wang, Y., Qi, Y., Yang, W., and Li, Y. (2020). Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.01247"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000450909","article-title":"Farnesoid X Receptor an Emerging Target to Combat Obesity","volume":"35","author":"Downes","year":"2017","journal-title":"Dig. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41401-021-00849-4","article-title":"FXR: Structures, biology, and drug development for NASH and fibrosis diseases","volume":"43","author":"Tian","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.tips.2007.03.002","article-title":"FXR: A promising target for the metabolic syndrome?","volume":"28","author":"Cariou","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1097-2765(03)00104-7","article-title":"A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR","volume":"11","author":"Downes","year":"2003","journal-title":"Mol. Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1016\/j.bmcl.2017.06.003","article-title":"A novel intestinal-restricted FXR agonist","volume":"27","author":"Wang","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/bmb\/ldaa006","article-title":"Obeticholic acid-a new therapy in PBC and NASH","volume":"133","author":"Chapman","year":"2020","journal-title":"Br. Med. Bull."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1210\/en.2003-1671","article-title":"Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes","volume":"145","author":"Fu","year":"2004","journal-title":"Endocrinology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cmet.2011.03.019","article-title":"FGF15\/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway","volume":"13","author":"Potthoff","year":"2011","journal-title":"Cell Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1074\/jbc.M808818200","article-title":"Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis","volume":"284","author":"Bhatnagar","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.tibs.2006.08.002","article-title":"FXR, a multipurpose nuclear receptor","volume":"31","author":"Lee","year":"2006","journal-title":"Trends Biochem. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/endo.143.5.8850","article-title":"Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity","volume":"143","author":"Tomlinson","year":"2002","journal-title":"Endocrinology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/hep.30810","article-title":"Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development","volume":"71","author":"Schumacher","year":"2020","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"355\u2013365.e351\u2013354","DOI":"10.1053\/j.gastro.2011.10.028","article-title":"Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis","volume":"142","author":"Modica","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1074\/jbc.M116.751404","article-title":"In Vitro and in Vivo Analyses Reveal Profound Effects of Fibroblast Growth Factor 16 as a Metabolic Regulator","volume":"292","author":"Rulifson","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Paraiso, I.L., Alcazar Magana, A., Alexiev, A., Sharpton, T.J., Maier, C.S., Kioussi, C., and Stevens, J.F. (2025). Reversing metabolic dysregulation in farnesoid X receptor knockout mice via gut microbiota modulation. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0331040"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"104386","DOI":"10.1016\/j.drudis.2025.104386","article-title":"Fexaramine as the intestine-specific farnesoid X receptor agonist: A promising agent to treat obesity and metabolic disorders","volume":"30","author":"Dabrowska","year":"2025","journal-title":"Drug Discov. Today"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Xiang, H., Xiang, H., Wang, S., Wu, P., Luo, Z., and Zhang, J. (2026). The role of bile acid-activated receptor TGR5 in inflammation and liver diseases. Front. Physiol., 17.","DOI":"10.3389\/fphys.2026.1747341"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2337\/db11-0030","article-title":"Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity","volume":"60","author":"Prawitt","year":"2011","journal-title":"Diabetes"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"26913","DOI":"10.1074\/jbc.M111.248203","article-title":"Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure","volume":"286","author":"Watanabe","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature04330","article-title":"Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation","volume":"439","author":"Watanabe","year":"2006","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/hep.29857","article-title":"Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism","volume":"68","author":"Pathak","year":"2018","journal-title":"Hepatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2009.08.001","article-title":"TGR5-mediated bile acid sensing controls glucose homeostasis","volume":"10","author":"Thomas","year":"2009","journal-title":"Cell Metab."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Zangerolamo, L., Carvalho, M., and Barbosa, H.C.L. (2025). The Critical Role of the Bile Acid Receptor TGR5 in Energy Homeostasis: Insights into Physiology and Therapeutic Potential. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146547"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.cmet.2021.04.009","article-title":"Hypothalamic bile acid-TGR5 signaling protects from obesity","volume":"33","author":"Fenelon","year":"2021","journal-title":"Cell Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s42255-021-00398-4","article-title":"Central anorexigenic actions of bile acids are mediated by TGR5","volume":"3","author":"Perino","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.bbrc.2013.03.031","article-title":"The TGR5 gene is expressed in human subcutaneous adipose tissue and is associated with obesity, weight loss and resting metabolic rate","volume":"433","author":"Svensson","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbrc.2005.01.139","article-title":"Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1","volume":"329","author":"Katsuma","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1210\/endo.130.1.1309325","article-title":"Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells","volume":"130","author":"Fehmann","year":"1992","journal-title":"Endocrinology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","article-title":"Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice","volume":"58","author":"Xu","year":"2009","journal-title":"Diabetes"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.metabol.2009.05.006","article-title":"Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery","volume":"58","author":"Nakatani","year":"2009","journal-title":"Metabolism"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1038\/oby.2009.102","article-title":"Serum bile acids are higher in humans with prior gastric bypass: Potential contribution to improved glucose and lipid metabolism","volume":"17","author":"Patti","year":"2009","journal-title":"Obesity"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s11605-021-04908-3","article-title":"Gastric Bypass Increases Circulating Bile Acids and Activates Hepatic Farnesoid X Receptor (FXR) but Requires Intact Peroxisome Proliferator Activator Receptor Alpha (PPARalpha) Signaling to Significantly Reduce Liver Fat Content","volume":"25","author":"Mazzini","year":"2021","journal-title":"J. Gastrointest. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"105265","DOI":"10.1016\/j.ebiom.2024.105265","article-title":"Alterations in bile acid kinetics after bariatric surgery in patients with obesity with or without type 2 diabetes","volume":"106","author":"Wahlstrom","year":"2024","journal-title":"eBioMedicine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature13135","article-title":"FXR is a molecular target for the effects of vertical sleeve gastrectomy","volume":"509","author":"Ryan","year":"2014","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1111\/jgh.70094","article-title":"Efficacy and Safety of Obeticholic Acid as Second-Line Therapy in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis","volume":"40","author":"Abreu","year":"2025","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/apt.14492","article-title":"Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis","volume":"47","author":"Hameed","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"105803","DOI":"10.1016\/j.cct.2019.06.017","article-title":"REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis","volume":"84","author":"Ratziu","year":"2019","journal-title":"Contemp. Clin. Trials"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_68","unstructured":"(2026, April 14). A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (LJN452) & Licogliflozin (LIK066) Combination Therapy and Each Monotherapy, Compared with Placebo for Treatment of Adult Patients with Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis. (ELIVATE). Clinicaltrials.gov Registry NCT04065841, 2019-002324-32 (EudraCT Number), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04065841."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.cgh.2022.07.024","article-title":"Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC","volume":"21","author":"Trauner","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: An adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"100544","DOI":"10.1016\/j.jhepr.2022.100544","article-title":"Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis","volume":"4","author":"Schramm","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/jvh.13608","article-title":"Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study","volume":"28","author":"Erken","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/HEP.0000000000000439","article-title":"Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study","volume":"78","author":"Anstee","year":"2023","journal-title":"Hepatology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.dld.2019.12.129","article-title":"Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results","volume":"52","author":"Lucas","year":"2020","journal-title":"Dig. Liver Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cgh.2021.12.044","article-title":"Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor\/Firsocostat","volume":"21","author":"Lawitz","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"105889","DOI":"10.1016\/j.cct.2019.105889","article-title":"A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial","volume":"88","author":"Pedrosa","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"ref_81","unstructured":"(2026, April 14). NASH EXploratory Single and COmbination Treatment (NEXSCOT): An Open Label, Multicenter, Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Various Single and Combination Treatments in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) Who Manifest a Non-Alcoholic Steatohepatitis (NASH)-Like Biomarker Phenotype. Clinicaltrials.gov Registry NCT04147195, 2019-000440-10 (EudraCT Number), Available online: https:\/\/cdn.clinicaltrials.gov\/large-docs\/95\/NCT04147195\/Prot_000.pdf."},{"key":"ref_82","unstructured":"(2026, April 14). A Randomized Patient-and-Physician Blinded, Placebo-Controlled, 24-Week Study to Assess the Safety, Tolerability and Efficacy of LMB763 in Patients with Diabetic Nephropathy. Clinicaltrials.gov Registry NCT03804879, 2018-002491-40 (EudraCT Number), Available online: https:\/\/www.patlynk.com\/trial\/NCT03804879."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J. Med. Chem."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/3081\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:41:48Z","timestamp":1776436908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/3081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":83,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15083081"],"URL":"https:\/\/doi.org\/10.3390\/jcm15083081","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]}}}